Alvotech And Bioventure Celebrate Egyptian Adalimumab Nod
Partnered AVT02 Biosimilar Rival To Humira Approved As Adalimumab-EVA
Executive Summary
Egypt has become the latest market in which Alvotech has received approval for its AVT02 biosimilar adalimumab rival to Humira. The product will be marketed by MENA partner Bioventure.